Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Illumina Inc. shares ILMN, -0.51% may be poised for a turnaround as the company hunts for a new CEO, Evercore ISI analysts wrote in a research note Friday. The analysts added the stock to their tactical outperform list, noting that “new CEOs can be powerful catalysts” and that a CEO hire in the coming weeks or months would give the new leadership a chance to be part of the fiscal year 2024 planning process.

At Illumina, new leadership could fuel turnaround, analysts say

Illumina (ILMN) boosts genomic capabilities in India with a new state-of-the-art Solutions Center.

Illumina (ILMN) Expands Presence in India With New Facility

Illumina is struggling to get customers to buy its newest products. Wall Street's estimates don't seem to account for that challenge.

Wall Street Thinks Illumina Stock Will Rise 27% in 1 Year. Here's Why That Probably Won't Happen.

LOS ANGELES, CA / ACCESSWIRE / August 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Stratasys board breached its fiduciary duties to shareholders.

FORMER GRAIL INVESTORS ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm

Exelixis

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?

EXEL or ILMN: Which Is the Better Value Stock Right Now?

LOS ANGELES, CA / ACCESSWIRE / August 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Stratasys board breached its fiduciary duties to shareholders.

LONG-TERM GRAIL SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm

Illumina, Inc. (NASDAQ:ILMN ) UBS MedTech, Tools and Genomics Summit 2023 Conference Transcript August 17, 2023 12:00 PM ET Executives Salli Schwartz - Vice President, Investor Relations Analysts John Sourbeer - UBS John Sourbeer Hi. I am John Sourbeer, one of the life sciences analyst here at UBS.

Illumina, Inc. (ILMN) Management Presents at UBS MedTech, Tools and Genomics Summit 2023 Conference (Transcript)

SAN DIEGO , Aug. 17, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the opening of a new office and state-of-the-art Illumina Solutions Center in Bengaluru, India. Illumina's expansion comes after 16 years of working closely with the company's channel partner in India, Premas Life Sciences.

Illumina expands genomics capabilities in India with opening of Solutions Center

Illumina is facing a slew of issues due to a botched acquisition. It's also not growing very quickly.

Down 15% in 2023, Should You Buy the Dip With Illumina Stock?

Illumina's acquisition of cancer test developer Grail has also faced heavy scrutiny from antitrust regulators in the U.S. and European Union.

SEC investigating Illumina over acquisition of cancer test developer Grail

The U.S. Securities and Exchange Commission (SEC) has begun an investigation into Illumina's $7.1 billion acquisition of cancer detection test maker Grail , the gene sequencing company said in a regulatory filing on Thursday.

US securities regulator probes Illumina over Grail deal

Illumina (ILMN) shipped 109 NovaSeq X instruments in the second quarter, boosting its supply capacity to more than 390 instruments for fiscal 2023.

Illumina (ILMN) Q2 Earnings Beat Estimates, Margins Contract

Citi analyst Patrick Donnelly cut his price target on Illumina to $150 from $180.

Illumina Slashes Guidance Amid 'Cautious' Consumer. What Wall Street Thinks.

Illumina, Inc. (NASDAQ:ILMN ) Q2 2023 Results Earnings Conference Call August 9, 2023 5:00 PM ET Company Participants Salli Schwartz - Vice President of Investor Relations Charles Dadswell - Interim Chief Executive Officer and General Counsel Joydeep Goswami - Chief Financial Officer, Chief Strategy and Corporate Development Officer Conference Call Participants Puneet Souda - SVB Leerink Dan Brennan - TD Cowen Dan Arias - Stifel Financial Vijay Kumar - Evercore ISI Tejas Savant - Morgan Stanley Sung Ji Nam - Scotia Capital John Sourbeer - UBS Operator Good day, ladies and gentlemen, and welcome to the Second Quarter 2023 Illumina Earnings Conference Call. At this time, all participants are in a listen-only mode.

Illumina, Inc. (ILMN) Q2 2023 Earnings Call Transcript

While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Illumina (ILMN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Illumina (ILMN) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.57 per share a year ago.

Illumina (ILMN) Tops Q2 Earnings and Revenue Estimates

Shares of Illumina Inc. slid 6.6% after hours on Wednesday after the DNA-sequencing company tempered its full-year sales outlook, amid a cautious consumer backdrop and a wobbly economic recovery in China. The company, whose equipment helps with genome analysis, said it expected full-year sales growth of around 1%.

Illumina stock falls, as ‘cautious consumer backdrop' tempers outlook

Illumina beat second-quarter expectations Wednesday, but delivered light earnings guidance for the year and ILMN stock tumbled.

Illumina Stock Crumbles As Earnings Guidance Completely Misses Forecasts

Illumina Inc lowered annual profit forecast on Wednesday, signaling weak demand for its sequencing and diagnostic services, sending the life sciences firm's shares down 7.5% after the bell.

Illumina cuts annual profit forecast

SAN DIEGO , Aug. 9, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Dr. Steven Barnard, Illumina's Vice President and Head of Global Advanced Science, will serve as its next Chief Technology Officer (CTO), effective immediately. Dr. Alex Aravanis, who held the position of CTO, will be departing Illumina to pursue another opportunity outside of the company.

Dr. Steven Barnard Appointed Chief Technology Officer

Revenue of $1.18 billion for Q2 2023, up 1% from Q2 2022 (up 3% on a constant currency basis) and up 8% from Q1 2023 Shipped 109 NovaSeq X instruments in Q2 2023; boosting our supply capacity to more than 390 instruments for fiscal year 2023 GAAP diluted loss per share of $(1.48) for Q2 2023, compared to GAAP diluted loss per share of $(3.40) for Q2 2022, which included $609 million in legal contingencies Non-GAAP diluted earnings per share of $0.32 for Q2 2023, compared to non-GAAP diluted earnings per share of $0.57 for Q2 2022 Now expect fiscal year 2023 consolidated revenue growth of approximately 1% from 2022, including Core Illumina revenue that is approximately flat with 2022 and GRAIL revenue still in the range of $90 million to $110 million Now expect GAAP diluted loss per share of $(2.08) to $(1.93) for fiscal year 2023 Now expect non-GAAP diluted earnings per share of $0.75 to $0.90 for fiscal year 2023 SAN DIEGO , Aug. 9, 2023 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the second quarter of fiscal year 2023, which include the consolidated financial results for GRAIL. "Illumina's second quarter consolidated revenue grew 8% sequentially from the first quarter, and we saw higher-than-anticipated NovaSeq X shipments," said Charles Dadswell, Interim Chief Executive Officer.

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2023

LOS ANGELES, CA / ACCESSWIRE / August 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Stratasys board breached its fiduciary duties to shareholders.

FORMER GRAIL SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Illumina, Inc. ("Illumina" or "the Company") (NASDAQ: ILMN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Stratasys board breached its fiduciary duties to shareholders.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Stratasys board breached its fiduciary duties to shareholders.

ONGOING GRAIL SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm

Guardant Health Inc

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (NASDAQ: GH), a leading precision oncology company, today announced an agreement with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, that resolves their pending litigation and promotes a shared resolution to advance the companies' long-term, commercial partnership. The three-year agreement includes a joint request to dismiss with prejudice the pending litigation between the companies, includ.

News for Illumina Stock (ILMN)